TLR8 Antibody (307D3.01) [Alexa Fluor® 488]
Novus Biologicals, part of Bio-Techne | Catalog # DDX0481A488-100
Key Product Details
Species Reactivity
Human, Mouse
Applications
Flow Cytometry, Immunocytochemistry/ Immunofluorescence
Label
Alexa Fluor 488 (Excitation = 488 nm, Emission = 515-545 nm)
Antibody Source
Monoclonal Mouse IgG1 Clone # 307D3.01
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
TLR8/CD288 was used as immunogen.
Reactivity Notes
Human, Mouse
Clonality
Monoclonal
Host
Mouse
Isotype
IgG1
Scientific Data Images for TLR8 Antibody (307D3.01) [Alexa Fluor® 488]
Immunocytochemistry/Immunofluorescence: TLR8 Antibody (307D3.01) [Alexa Fluor (R) 488] [DDX0481A488-100] - Staining of human tonsil frozen section.
Applications for TLR8 Antibody (307D3.01) [Alexa Fluor® 488]
Application
Recommended Usage
Flow Cytometry
1:10-1:1000
Immunocytochemistry/ Immunofluorescence
1:10-1:2000
Formulation, Preparation, and Storage
Purification
Ion exchange chromatography
Formulation
PBS and 50% Glycerol
Preservative
No Preservative
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at -20C in the dark. Avoid freeze-thaw cycles.
Background: TLR8
TLR8 is highly similar to TLR7 and both pathways are mediated by the adapter protein MyD88 to signal through IFN regulatory factor 7 (IRF7) and nuclear factor (NF)-kappaB (1-3,5). However, TLR7 recognizes guanosine and GU-rich ssRNA, while TLR8 recognizes uridine and AU-rich sequences (2,5). TLR7/TLR8 agonists, including derivatives of the immunostimulatory imiquimod, have been shown to be a promising cancer therapy capable of providing anticancer signals to antigen presenting cells (APCs), with many agonists being tested in both pre-clinical and clinical trials (6). Similarly, studies suggest that agonists for TLR8, in combination with other individual TLR agonists and antagonists, may also be useful for treating inflammatory allergic diseases, such as allergic rhinitis (7).
References
1. Sakaniwa, K., & Shimizu, T. (2020). Targeting the innate immune receptor TLR8 using small-molecule agents. Acta crystallographica. Section D, Structural biology, 76(Pt 7). https://doi.org/10.1107/S2059798320006518
2. Cervantes, J. L., Weinerman, B., Basole, C., & Salazar, J. C. (2012). TLR8: the forgotten relative revindicated. Cellular & molecular immunology. https://doi.org/10.1038/cmi.2012.38
3. Ohto, U., Tanji, H., & Shimizu, T. (2014). Structure and function of toll-like receptor 8. Microbes and infection. https://doi.org/10.1016/j.micinf.2014.01.007
4. Uniprot (Q9NR97)
5. Jannuzzi, G. P., de Almeida, J., Paulo, L., de Almeida, S. R., & Ferreira, K. S. (2020). Intracellular PRRs Activation in Targeting the Immune Response Against Fungal Infections. Frontiers in cellular and infection microbiology. https://doi.org/10.3389/fcimb.2020.591970
6. Frega, G., Wu, Q., Le Naour, J., Vacchelli, E., Galluzzi, L., Kroemer, G., & Kepp, O. (2020). Trial Watch: experimental TLR7/TLR8 agonists for oncological indications. Oncoimmunology. https://doi.org/10.1080/2162402X.2020.1796002
7. Golshiri-Isfahani, A., Amizadeh, M., & Arababadi, M. K. (2018). The roles of toll like receptor 3, 7 and 8 in allergic rhinitis pathogenesis. Allergologia et immunopathologia. https://doi.org/10.1016/j.aller.2017.09.026
Long Name
Toll-like Receptor 8
Alternate Names
CD288
Gene Symbol
TLR8
Additional TLR8 Products
Product Documents for TLR8 Antibody (307D3.01) [Alexa Fluor® 488]
Product Specific Notices for TLR8 Antibody (307D3.01) [Alexa Fluor® 488]
This product is manufactured by Eurobio Scientific (formerly Dendritics) and distributed by Novus Biologicals.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...